Introduction {#sec1}
============

Obesity is associated with the development of insulin resistance, linked to the pathogenesis of type 2 diabetes (T2D) and cardiovascular disease (CVD). Nonetheless, adverse metabolic sequelae are not uniformly observed in obese individuals. While subjects with abdominal obesity display an increased prevalence of CVD, similarly overweight individuals with gluteofemoral fat distribution are protected from cardiometabolic disorders ([@bib54]). Consistent with epidemiologic findings, physiological studies have shown that the gluteofemoral white adipose tissue (WAT) depot displays differential fatty acid (FA) handling compared to the subcutaneous (SC) abdominal WAT depot ([@bib23; @bib24]). By favoring the long-term storage of FAs, gluteofemoral fat may protect skeletal muscle from ectopic lipid accumulation and lipotoxicity, which triggers insulin resistance ([@bib42]). Gluteofemoral fat may also contribute to improved metabolic risk by secreting a more beneficial adipocytokine profile than SC abdominal and visceral fat ([@bib13; @bib50]). Adipose-derived hormones and cytokines directly modulate systemic insulin sensitivity ([@bib37]).

WAT expands by an increase in adipocyte number (hyperplasia) and size (hypertrophy) ([@bib46; @bib49]). Adipocytes derive from mesenchymal stem cells (MSCs) and preadipocytes that reside in the stromovascular fraction of WAT. Several clinical and experimental studies indicate that discrete fat depots arise from distinct precursors with inherently different proliferative and adipogenic properties ([@bib3; @bib44; @bib47]). It is further postulated that developmental pathways play a key role in establishing the distinct identities of adipose progenitors from separate locations and thus in determining (1) the relative size of fat depots, by determining adipocyte number (and size) within each depot, and (2) the function of WAT depots, by modulating expression of adipogenic genes and their downstream targets. Consistent with this hypothesis, stromovascular cells (SVCs) isolated from discrete fat depots exhibit distinct developmental gene expression profiles ([@bib15; @bib48]). Furthermore, in a genome-wide association study (GWAS) meta-analysis, 4 of the 13 identified loci associated with body mass index (BMI)-adjusted waist-to-hip ratio (WHR), a measure of body fat distribution, mapped in or near developmental genes ([@bib20]). Notably two of these, *RSPO3* and *ZNRF3*, constitute WNT signaling modulators. A locus near *RSPO3*, distinct from the WHR-associated signal, was also shown to be associated with bone mineral density (BMD) at genome-wide significance ([@bib10; @bib12]).

WNTs are a family of 19 secreted glycoproteins acting locally via multiple pathways to regulate adult tissue homeostasis ([@bib7]). In the β-catenin ("canonical") cascade, WNT binding to Frizzled (FZD) receptors and low-density lipoprotein receptor-related protein (LRP) 5/6 co-receptors leads to nuclear accumulation of the transcriptional co-activator β-catenin, which, paired with LEF/TCF transcription factors, dose-dependently modulates (generally activates) WNT target gene expression. WNTs also signal through "non-canonical" pathways. In the planar cell polarity (PCP) pathway, WNT binding to FZD activates JNK and stimulates AP1-dependent transcription. In the WNT/Ca^2+^ pathway, WNT/FZD interaction triggers intracellular Ca^2+^ release and calmodulin-dependent protein kinase-2A (CAMK2A) activation. Canonical and non-canonical pathways are thought to be mutually antagonistic ([@bib19; @bib53]).

WNT signaling is a key regulator of MSC biology ([@bib6; @bib26]). Canonical signaling, the best-studied pathway, which critically relies on LRP5 and LRP6 co-receptors for activation, has been shown to repress adipogenesis and stimulate osteoblastogenesis. Accordingly, patients carrying rare gain-of-function (GoF) *LRP5* mutations exhibit high bone mass (HBM) ([@bib5; @bib27]). Reciprocally, rare loss-of-function (LoF) *LRP5* mutations lead to osteoporosis ([@bib1; @bib16]), which, in a study of 12 affected probands from two families, was coupled with an increased prevalence of T2D ([@bib41]). Finally, rare inactivating missense mutations in *LRP6* result in autosomal dominant CVD, features of the metabolic syndrome, and osteoporosis ([@bib29; @bib45]). Prompted by these and the aforementioned GWAS findings ([@bib20]), we sought to determine the role of LRP5 in human WAT biology and fat distribution. Our interest in LRP5 was also stimulated by preliminary analyses showing that it was differentially expressed between SC abdominal and gluteal SVCs. Furthermore, WAT *LRP5* mRNA levels correlated with measures of regional adiposity and systemic insulin sensitivity. Herein we demonstrate that LRP5-driven β-catenin signaling regulates adipose progenitor proliferation and differentiation in a dose- and depot-specific manner, thereby modulating human body fat distribution.

Results {#sec2}
=======

HBM-Causing *LRP5* Mutations Are Associated with Lower-Body Fat Accumulation {#sec2.1}
----------------------------------------------------------------------------

We examined the adipose and metabolic phenotype of three pedigrees with extreme HBM secondary to rare heterozygous GoF *LRP5* mutations. Compared to age-, gender-, and BMI-matched Oxford Biobank (OBB) controls, HBM *LRP5* mutation carriers had an increased amount of lower-body fat as determined by whole-body dual energy X-ray absorptiometry (DXA). In particular, all overweight/obese (BMI ≥ 25) HBM subjects with *LRP5* mutations (n = 5 of 6 individuals in total; S1--S3, S5, S6) had a higher tissue percent fat specifically in their legs ([Table 1](#tbl1){ref-type="table"}). Furthermore, all affected individuals displayed lower android/leg, android/total, and central/peripheral fat mass ratios ([Table 1](#tbl1){ref-type="table"}). This adipose phenotype was not driven by the HBM, as HBM *LRP5* mutation carriers had a decreased upper-to-lower-body fat ratio even when compared with matched non-*LRP5* HBM cases (n = 18) ([Table 2](#tbl2){ref-type="table"}). Similar results were obtained when comparing age-, gender-, and BMI-adjusted DXA data from *LRP5* HBM cases versus the rest of the (non-*LRP5*) HBM cohort (n = 134) ([Table S1](#app2){ref-type="sec"}). *LRP5* HBM individuals also exhibited enhanced insulin sensitivity as determined by lower HOMA-IR and fasting insulin levels relative to OBB controls ([Tables 1](#tbl1){ref-type="table"} and [S2](#app2){ref-type="sec"}). One exception was subject S2 (68 years old), whom we were able to compare only with 49--50 year old gender- and BMI-matched controls. Finally, ex vivo gene expression analyses of fractionated SC adipose cells revealed lower inflammatory gene transcript levels in *LRP5* HBM individuals (n = 4; subjects S1, S4--S6) versus OBB controls (n = 24--25) ([Figure S1](#app2){ref-type="sec"}A). We conclude that rare, GoF *LRP5* mutations are associated with enhanced lower-body fat accumulation, a favorable metabolic profile, and reduced WAT inflammation.

A Low BMD-Associated Allele in *LRP5* Correlates with Upper-Body Fat Accumulation {#sec2.2}
---------------------------------------------------------------------------------

To further investigate the role of LRP5 in regulating regional adiposity, we explored the association between a common *LRP5* single nucleotide polymorphism (SNP) and DXA-derived measures of fat distribution in 3,289 OBB volunteers. Rs599083 is an intronic SNP shown to be significantly associated with lumbar spine BMD in a GWAS meta-analysis ([@bib39]). Of note, rs599083 showed modest evidence of association with fat distribution within the OBB cohort ([Table 3](#tbl3){ref-type="table"}). Specifically, the low BMD-associated minor allele at this locus correlated with increased age-, gender-, and BMI-adjusted android tissue percent fat and android/total and central/peripheral fat mass ratios. These associations were attenuated following adjustment for BMD, in keeping with rs599083 being an overlapping signal for bone and fat traits ([Table 3](#tbl3){ref-type="table"}). Based on the established association between LoF *LRP5* mutations and osteoporosis ([@bib1; @bib16]), we presume that this allele is associated with reduced LRP5 function, which, according to gene expression analyses from 37 OBB subjects ([Figure S2](#app2){ref-type="sec"}A) and eQTL data from the MuTHER consortium (<http://www.muther.ac.uk>), is not driven by changes in adipose *LRP5* mRNA levels. We also undertook histological analyses of SC abdominal WAT from 18 overweight and obese individuals. Subject characteristics are shown in [Table S3](#app2){ref-type="sec"}. These revealed that adipocyte numbers in android fat tended to be lower in carriers of the low BMD-associated allele at rs599083 (GG, GT) versus homozygous carriers of the common allele (TT) (p = 0.05). This effect was primarily due to a reduction in small adipocytes ([Figures S2](#app2){ref-type="sec"}B and S2C). No associations between rs599083 and anthropometric measures of fat distribution were identified within the OBB ([Table S4](#app2){ref-type="sec"}). Nonetheless, and consistent with our findings, this SNP was weakly associated with BMI-adjusted waist circumference (WC) in females (p = 0.001 for association, β = 0.016 for the minor allele) in the publicly available sex-stratified GIANT data set ([@bib38]). It should be noted that associations between waist and hip circumferences and the respective regional fat masses (android and gynoid) within the OBB had rho values of ∼0.5 ([Table S5](#app2){ref-type="sec"}). We conclude that, mirroring the effects of rare GoF *LRP5* mutations, a common *LRP5* allele that is presumably associated with reduced LRP5 function correlates with modestly increased upper-body fat accumulation.

LRP5 Is More Highly Expressed in Abdominal Than Gluteal Adipose Progenitors {#sec2.3}
---------------------------------------------------------------------------

In order to gain mechanistic insights into the effects of LRP5 on fat distribution, we examined the *LRP5* gene expression pattern in paired SC abdominal and gluteal fat from 20 lean and 20 obese OBB volunteers ([Table S6](#app2){ref-type="sec"}). *LRP5* expression was identical in the two depots, albeit lower in obese versus lean subjects ([Figure 1](#fig1){ref-type="fig"}A). We also compared *LRP5* gene expression in paired SC abdominal and visceral fat from 16 subjects undergoing surgery. *LRP5* mRNA levels were higher in SC abdominal WAT, in contrast to *RSPO3* gene expression, which was higher in visceral versus SC fat ([Figures 1](#fig1){ref-type="fig"}B and 1C). We next determined the expression of *LRP5* in fractionated SC abdominal and gluteal WAT ([Figure 1](#fig1){ref-type="fig"}D). *LRP5* gene expression was higher in mature adipocytes compared with SVCs from both depots. No difference in *LRP5* transcript levels was observed between abdominal and gluteal adipocytes. In contrast, *LRP5* expression was significantly higher in abdominal versus gluteal SVCs (p = 4 × 10^−6^, with Bonferroni correction). We corroborated this finding by demonstrating higher abdominal LRP5 protein level in five independent pairs of primary and one pair of immortalized (see below) SVCs ([Figure 1](#fig1){ref-type="fig"}E). Finally, we examined the *LRP5* gene expression profile in differentiating SVCs from a further five subjects. *LRP5* mRNA levels were higher in undifferentiated abdominal versus gluteal SVCs but, following induction of adipogenesis, became indistinguishable between abdominal and gluteal adipocytes ([Figure 1](#fig1){ref-type="fig"}F). In summary, *LRP5* is more highly expressed in SC versus visceral fat. Furthermore, when comparing SC depots, *LRP5* mRNA and protein levels are specifically higher in abdominal compared with gluteal adipose progenitors.

To determine whether different patterns of fat distribution (upper versus lower) are associated with differences in WAT *LRP5* gene expression, we analyzed *LRP5* mRNA levels in paired SC abdominal and gluteal fat from 47 females recruited based on WC ([Table S7](#app2){ref-type="sec"}). A WC ≥ 80 cm is a measure of central obesity, with increased CVD risk in Europid women as defined by the International Diabetes Federation ([@bib2]). *LRP5* gene expression was selectively lower in the gluteal depot of women with android obesity (WC ≥ 80 cm) ([Figure 1](#fig1){ref-type="fig"}G). Furthermore, in partial correlation analyses, gluteal (but not abdominal) *LRP5* expression correlated negatively with upper-body fat accumulation, systemic insulin resistance, and markers of inflammation after adjustment for age, BMI, and menopausal status ([Table S8](#app2){ref-type="sec"}). We conclude that reduced gluteal WAT *LRP5* gene expression correlates with upper-body fat accumulation and an adverse metabolic and inflammatory profile.

*LRP5* Knockdown Has Distinct Biological Effects in Abdominal and Gluteal Progenitors {#sec2.4}
-------------------------------------------------------------------------------------

In light of our earlier findings, we investigated the role of LRP5 in depot-specific adipose progenitor biology using an immortalized pair of SC abdominal and gluteal SVCs. While displaying enhanced proliferation and adipogenesis (our unpublished data), these cells retain their depot-specific gene expression signatures ([@bib35]). Stable *LRP5* knockdown (KD) in these immortalized SVCs was achieved by lentiviral transduction with two independent shRNAs ([Figures 2](#fig2){ref-type="fig"}A and [S3](#app2){ref-type="sec"}A). Both shRNAs targeted the two protein-coding *LRP5* transcripts (<http://www.ensembl.org>) and were specific to *LRP5* as no change in *LRP6* mRNA levels was detected. The aim of these experiments was to compare the biological effects of equivalent *LRP5* gene dosage reduction in abdominal and gluteal SVCs rather than to completely silence *LRP5*. Clone TRCN0000033400 (sh400) gave the more efficient KD. As intended, the KD magnitude was equivalent in abdominal and gluteal progenitors (see *LRP5* gene expression panel in [Figure 2](#fig2){ref-type="fig"}A). Nonetheless, due to the higher *LRP5* gene expression in abdominal SVCs, the percentage KD achieved was 33% in abdominal versus 73% in gluteal cells compared to scrambled shRNA-transduced SVCs. Less efficient *LRP5* gene silencing (24% in abdominal versus 56% in gluteal SVCs) was achieved with shRNA clone TRCN0000033401 (sh401); again, in absolute terms *LRP5* KD was near-identical in abdominal and gluteal cells ([Figure S3](#app2){ref-type="sec"}A). *LRP5* KD using either shRNA was associated with impaired proliferation in both abdominal and gluteal SVCs ([Figure 2](#fig2){ref-type="fig"}B and our unpublished data), a finding confirmed by *LRP5* KD in primary SVCs derived from a female subject ([Figure S4](#app2){ref-type="sec"}A). Decreased *LRP5* expression in gluteal cells was also associated with a marked and dose-dependent inhibition of differentiation as ascertained by lipid accumulation and adipogenic gene expression ([Figures 2](#fig2){ref-type="fig"}C, 2E, [S3](#app2){ref-type="sec"}B, and S3D). *LRP5*-KD gluteal adipocytes further exhibited heightened inflammation as determined by increased *IL6* and *MCP1* transcript levels ([Figures S1](#app2){ref-type="sec"}B and S1C). In contrast, *LRP5* KD in abdominal progenitors using sh400 was not associated with changes in adipogenesis or adipocyte inflammation ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S1](#app2){ref-type="sec"}B); more strikingly, stable expression of sh401 in abdominal SVCs led to enhanced differentiation ([Figures S3](#app2){ref-type="sec"}B and S3C). Similar effects on adipogenesis were observed following sh400-mediated *LRP5* KD in female primary adipose SVCs ([Figure S4](#app2){ref-type="sec"}B). In summary, equivalent absolute KD of *LRP5* in abdominal and gluteal progenitors leads to distinct biological outcomes that may be driven by the differential *LRP5* gene expression between the two progenitor populations.

LRP5 KD Dose-Dependently Impairs Canonical WNT Signaling in Adipose Progenitors {#sec2.5}
-------------------------------------------------------------------------------

We examined which WNT pathway(s) were responsible for the biological actions of LRP5. *LRP5* KD in both abdominal and gluteal cells led to impaired canonical WNT signaling, as determined by decreased active β-catenin and phosphorylated (active) LRP5/6 protein levels and reduced expression of *AXIN2*, a universal β-catenin target gene ([Figures 3](#fig3){ref-type="fig"}A and [S3](#app2){ref-type="sec"}E). Given that β-catenin is generally thought to restrain adipogenesis, these findings are prima facie counterintuitive to the block in differentiation seen in gluteal SVCs. We next examined whether non-canonical WNT pathways were differentially regulated following *LRP5* KD in abdominal and gluteal progenitors. However, both PCP and WNT/Ca^2+^ signaling were modulated in a directionally uniform manner in *LRP5*-KD cells. Specifically, *LRP5* KD using sh400 (i.e., the more efficient shRNA) led to increased JNK phosphorylation and elevated *IL6* expression in both abdominal and gluteal SVCs, consistent with PCP pathway activation ([Figure 3](#fig3){ref-type="fig"}A). Conversely, the phosphorylated to total CAMK2A ratio was uniformly decreased in abdominal and gluteal *LRP5*-KD cells ([Figures 3](#fig3){ref-type="fig"}A, [S3](#app2){ref-type="sec"}E, and S3F). LRP5 was shown to promote insulin signaling and adipogenesis in 3T3-L1 preadipocytes ([@bib34]). Hence, we asked whether insulin/IGF1 signaling was driving the actions of LRP5 on adipose progenitor biology. As shown in [Figures 3](#fig3){ref-type="fig"}B and [S3](#app2){ref-type="sec"}G, however, neither basal nor stimulated phosphorylation of IRS1, AKT, or ERK1/2 following treatment with 100 nM insulin (i.e., the same dose used to induce adipogenesis) were altered with *LRP5* KD. Consistent with these data, no baseline change in insulin receptor (*INSR*) gene expression was detected in response to *LRP5* KD in either abdominal or gluteal SVCs ([Figures 3](#fig3){ref-type="fig"}C and [S3](#app2){ref-type="sec"}H). We confirmed and extended these findings in *LRP5*-KD primary SVCs treated with a more physiological insulin dose (10 nM) ([Figure 3](#fig3){ref-type="fig"}D).

β-catenin has been shown to dose-dependently modulate target gene expression and stem/progenitor cell cycling and fate-determination ([@bib21; @bib25; @bib28]). Given the graded effects of *LRP5* KD on abdominal and gluteal SVC proliferation and differentiation, we examined whether active β-catenin levels and β-catenin target genes were regulated in a dose-like fashion. This was indeed the case ([Figures 4](#fig4){ref-type="fig"}A and 4B). Mirroring these findings, selectively attenuating β-catenin transcriptional activity with use of the small-molecule inhibitor iCRT14 ([@bib17]) dose-dependently impaired adipogenesis in immortalized gluteal SVCs ([Figure 4](#fig4){ref-type="fig"}C). In contrast, low-dose iCTR14 (1 μM) enhanced adipogenesis in abdominal progenitors while higher dose (10 μM) impaired differentiation, albeit to a lesser extent than the equivalent dose in gluteal cells. Accordingly, iCTR14-induced inhibition of β-catenin-dependent promoter activity was more pronounced in gluteal than abdominal SVCs. iCRT14 also dose-dependently impaired adipose progenitor proliferation. As expected, this effect was more marked in gluteal versus abdominal cells ([Figure 4](#fig4){ref-type="fig"}C). We conclude that the biological effects of *LRP5* KD in adipose progenitors are driven by dose-dependent reductions in β-catenin transcriptional activity, which, for an equivalent decrease in *LRP5* gene dosage, is more potently blocked in gluteal than abdominal SVCs.

Discussion {#sec3}
==========

Fat distribution is a heritable trait that strongly predicts diabetes and CVD risk independent of obesity. In this study we identify the WNT co-receptor LRP5 as a regulator of adipose progenitor biology and regional adiposity. By examining three HBM pedigrees, we show that rare GoF *LRP5* mutations are associated with an increased amount of lower-body fat. Complimentary to these findings we also demonstrate, through the analysis of DXA data from \> 3,000 individuals, that the minor allele of a common SNP in *LRP5* associated with low BMD correlates with modestly increased upper-body fat accumulation. From the direction of its effect upon BMD, this allele is likely to be associated with reduced LRP5 function. Based on our in vitro KD studies, the increased central adiposity observed in rs599083 minor allele carriers is likely to be driven by enhanced cellularity of the SC abdominal relative to the gluteofemoral fat depot. Nonetheless, in these same experiments, *LRP5*-KD SC abdominal SVCs exhibited impaired proliferation and enhanced inflammation. We speculate that this is likely to impact negatively on the size and quality of the SVC pool and ultimately adipocyte number in this depot, too, a hypothesis consistent with the histological analysis of SC abdominal WAT from a limited number of rs599083 minor versus homozygous major allele carriers ([Figures S2](#app2){ref-type="sec"}B and S2C).

*LRP5* HBM individuals also exhibited enhanced insulin sensitivity versus age-, gender-, and BMI-matched controls. This may be at least partly due to their more favorable body fat distribution coupled with greater WAT cellularity (i.e., fat storage capacity, thought to protect against ectopic lipid deposition and lipotoxicity) due to enhanced SVC proliferation and, in the case of gluteal SVCs, potentially also differentiation. In contrast, rs599083 was not associated with T2D risk or measures of BMI-adjusted insulin sensitivity in publically available data sets from the DIAGRAM ([@bib33]) and MAGIC ([@bib30]) consortia, respectively. However, power to detect phenotypic associations between WHR- and BMI-associated variants and related metabolic parameters can be low. Accordingly, not all signals associated with fat distribution showed significant associations with surrogates of insulin resistance in the meta-analysis by Heid et al. ([@bib20]). This is likely due to the limited power to detect downstream phenotypes, given the relatively low effect sizes at individual loci, even when the overall phenotypic associations are strong.

The lack of and weak association between rs599083 and anthropometric measures of fat distribution in the OBB ([Table S4](#app2){ref-type="sec"}) and GIANT data sets, respectively, is notable. In this regard we detected only modest age-, gender-, and BMI-adjusted correlations between anthropometric and DXA-derived measures of fat distribution within the OBB ([Table S5](#app2){ref-type="sec"}). Furthermore, alterations in body shape and/or skeletal geometry consequent to the actions of LRP5 on bone may mask the associations between *LRP5* variants and anthropometric surrogates of adiposity. In keeping with this, rs3736228, a non-synonymous exonic SNP in *LRP5* that is in linkage disequilibrium with rs599083, was shown to modulate femoral neck width, femoral shaft geometry, and vertebral body size ([@bib4; @bib51]). Moreover, in a study of 258 individuals with unexplained HBM, HBM cases had significantly broader skeletal frames compared with controls ([@bib18]). Accordingly, we detected no consistent differences in anthropometric measures of fat distribution between HBM *LRP5* mutation carriers and matched OBB controls ([Table S2](#app2){ref-type="sec"}). Finally, distinct from the WAT expression pattern of *LRP5*, *RSPO3* ([Figure 1](#fig1){ref-type="fig"}C) and *ZNRF3* ([@bib43]) are more highly expressed in visceral versus SC fat. These contrasting gene expression profiles may also account for the more robust association between SNPs within these genes and body fat distribution in GWAS.

Much of the impetus for this work was based on an earlier search for WNT pathway genes that were differentially expressed between SC abdominal and gluteal SVCs. We had reasoned that these may underlie intrinsic differences in WNT pathway tone (signal strength) and/or specificity (canonical versus non-canonical pathway activation) between abdominal and gluteal progenitors. Such changes in turn might endow SVCs from these depots with distinct functional properties, thereby driving changes in fat distribution. As part of those analyses, *LRP5* was found to be more highly expressed in abdominal versus gluteal progenitors. Herein we show that, consistent with our original hypothesis, equivalent magnitude of *LRP5* KD in abdominal and gluteal SVCs leads to markedly different proportional reduction in LRP5 levels/activity and distinct biological outcomes; *LRP5* KD impaired proliferation to a greater extent in immortalized gluteal than abdominal progenitors ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, while *LRP5* KD in gluteal SVCs led to impaired adipogenesis, differentiation in abdominal cells was unchanged and even enhanced following modest and low-level *LRP5* KD, respectively. Finally, compared with controls, gluteal but not abdominal *LRP5*-KD adipocytes were inflamed. We speculate that by modulating regional WAT cellularity, these diverse biological responses underlie, at least partly, the effects of LRP5 on fat distribution. Moreover, they are rooted in the different levels of *LRP5* expression between abdominal and gluteal progenitors coupled with dose-dependent effects of LRP5 on SVC function. As such, due to the lower *LRP5* transcript and protein levels in gluteal versus abdominal SVCs ([Figures 1](#fig1){ref-type="fig"}D and 1E), gluteal progenitors are likely to be more sensitive than abdominal progenitors to changes in (1) LRP5 function, due to missense variants, and (2) *LRP5* mRNA levels, e.g., decreased expression driven by obesity or intronic SNPs. In agreement with this hypothesis, we found that *LRP5* gene expression in gluteal but not SC abdominal WAT correlated negatively with upper-body fat accumulation in females ([Table S8](#app2){ref-type="sec"}). Adipocyte size (an inverse correlate of WAT cellularity) has also been reported to be larger in the gluteal versus abdominal depot of women ([@bib52]). Complicating the interpretation of this latter finding, however, hormonal signals---e.g., sex-steroids---can interact with WNT signaling tone in vivo to modulate adipocyte size ([@bib11]). Additionally, in weight-gaining adults, abdominal WAT is thought to expand by hypertrophy ([@bib46; @bib49]) and gluteofemoral WAT by hyperplasia ([@bib49]).

Mechanistically, the effects of *LRP5* KD on SVC proliferation arise from inhibition of canonical WNT signaling. This conclusion was confirmed by the dose-dependent decrease in both β-catenin-driven promoter activity and proliferation in adipose SVCs following treatment with iCTR14. Furthermore, the link between adipose cell inflammation and WNT/LRP5 signaling is likely to have its basis in the mutually antagonistic actions of the β-catenin and PCP pathways ([@bib19]). Thus, suppressing canonical WNT signaling promotes JNK activation, thereby driving inflammation. Likewise, the enhanced differentiation seen in abdominal cells following low-level *LRP5*-KD is in keeping with the well-established anti-adipogenic action of WNT/β-catenin signaling. In contrast, further reduction in LRP5 levels progressively restrains adipocyte differentiation. In line with this, *LRP5*-KD gluteal SVCs, which exhibit the lowest LRP5 protein levels, display a "paradoxical" block in adipogenesis. The anti-adipogenic actions of LRP5 deficiency are not mediated via altered non-canonical WNT signaling, as neither the PCP nor the WNT/Ca^2+^ pathways were differentially modulated in abdominal versus gluteal *LRP5*-KD cells. Moreover, in contrast to Palsgaard et al. ([@bib34]), we were unable to detect any changes in insulin/IGF1 pathway activity in response to *LRP5* KD ([Figures 3](#fig3){ref-type="fig"}B and [S3](#app2){ref-type="sec"}G). Instead, utilizing iCRT14, we demonstrate that the anti-adipogenic effect of LRP5 deficiency is likely to be driven by impaired β-catenin transcriptional activity ([Figure 4](#fig4){ref-type="fig"}C). We note that we have not corroborated this conclusion by rescuing adipogenesis in *LRP5*-KD gluteal SVCs through augmenting β-catenin signaling. Such a rescue experiment, however, is technically challenging, since constitutively increasing β-catenin activity in adipose progenitors potently blocks adipogenesis ([@bib6]). Hence, rescuing differentiation in *LRP5*-KD gluteal cells would require precisely titrating the degree as well as the timing and duration of β-catenin signaling activation prior to and/or during differentiation. Our results suggest that, similar to its mode of action in stem/progenitor cells from other organs/tissues ([@bib21; @bib25; @bib28]), canonical WNT signaling in human adipose SVCs is more complex than an on/off switch. Rather, it is associated with different biological outcomes dependent on a gradient of β-catenin transcriptional activity. Finally, in conjunction with earlier findings ([@bib9; @bib40]), our data also show that autonomous as well as non-autonomous WNT/β-catenin signals can both promote and inhibit adipogenesis.

In summary, we have established that LRP5 acts by titrating β-catenin signal strength to modulate adipose progenitor biology in a depot-specific manner, thus promoting lower-body fat accumulation. Rational manipulation of *LRP5* expression/activity to achieve a more beneficial pattern of fat distribution may offer a potential approach to treat obesity-associated CVD. We note in this respect that treatment with humanized antibodies against SOST (a secreted LRP5 antagonist) is currently in phase III trials for osteoporosis management ([@bib31]). Once such treatments become the mainstay for osteoporosis, it will be important to determine their effects on fat distribution and metabolic health.

Experimental Procedures {#sec4}
=======================

Study Population and Sample Collection {#sec4.1}
--------------------------------------

Control study subjects were recruited from the OBB, a population-based collection of healthy subjects aged 30--50 years (<http://www.oxfordbiobank.org.uk>). HBM *LRP5* mutation carriers were recruited from the UK-based HBM study cohort ([@bib18]) (see [Supplemental Information](#app2){ref-type="sec"}). Paired SC abdominal and gluteal WAT specimens were obtained by needle biopsy as described ([@bib32]). Paired SC abdominal and visceral fat samples were obtained from patients undergoing elective surgery as part of the MolSURG study. All studies were approved by the Oxfordshire Clinical Research Ethics Committee and the Bath multi-centre Research Ethics Committee, and all volunteers gave written, informed consent. Other aspects of the study in pre- and post-menopausal women have previously been reported ([@bib22]).

Dual Energy X-Ray Absorptiometry {#sec4.2}
--------------------------------

Whole-body DXAs were performed using a Lunar iDXA (GE Healthcare). Acquired images were processed using enCORE v14.1 software. Central-to-peripheral fat ratio was calculated as android fat (g) ÷ (arms + legs) fat (g).

Isolation, Culture, and Differentiation of Human SVCs {#sec4.3}
-----------------------------------------------------

SVCs were isolated from WAT biopsies, cultured, and differentiated as described ([@bib8]) (see [Supplemental Information](#app2){ref-type="sec"}). SVCs isolated from a male subject were immortalized by co-expressing human telomerase reverse transcriptase and human papillomavirus type-16 E7 oncoprotein ([@bib35]). To study the effects of iCRT14 (Sigma-Aldrich) on adipogenesis, SVCs were seeded in type I collagen-coated 96-well plates. Culture media were replaced after 24 hr with growth media containing iCRT14 (1 μM or 10 μM) or DMSO. Confluent cells were differentiated 48 hr later in the same concentration of iCRT14 (or DMSO) throughout for 21 days. Media were changed every 2--3 days. Intracellular lipid levels were quantified using the AdipoRed assay reagent (Lonza) and a CytoFluor Multi-Well Plate Reader series 4000 (PerSeptive Biosystems).

Estimation of Cell Doubling Time {#sec4.4}
--------------------------------

Equal numbers of control and *LRP5*-KD SVCs, i.e., 400,000 or 150,000, were seeded in T175 and T75 flasks, respectively. Cells were trypsinized and double counted every 72 hr. Doubling time was calculated using the formula T~d~ *=* (t~2~ *−* t~1~) × \[log(2) ÷ log(q~2~ ÷ q~1~)\], where t = time (days) and q = cell number.

Lentiviral Constructs and Generation of Stable Cell Lines {#sec4.5}
---------------------------------------------------------

MISSION *LRP5* shRNA and control plasmid DNA vectors were obtained from Sigma-Aldrich. The 7TFP WNT reporter lentiviral vector ([@bib14]) was obtained from Addgene. Lentiviral particles were produced by transient co-transfection of HEK293 cells with the vector of interest and packaging vectors (MISSION \[Sigma-Aldrich\] and ViraPower \[Invitrogen\] packaging mixes). Stable cell lines were generated by transduction of SVCs with lentiviral particles followed by selection in growth media containing 2 μg/ml puromycin.

Insulin Stimulation Studies of SVCs {#sec4.6}
-----------------------------------

Stimulation experiments with 10 nM or 100 nM insulin (Sigma-Aldrich) were performed as described ([@bib34]).

Genotyping, Quantitative Real-Time PCR, Western Blot Analyses, and Measurement of Adipocyte Size and Number {#sec4.7}
-----------------------------------------------------------------------------------------------------------

Genotyping and qRT-PCR were performed using TaqMan assays. Western blot analyses were performed using standard protocols. Adipocyte sizing was performed using a histological method. Full details are found in [Supplemental Information](#app2){ref-type="sec"}.

Luciferase Reporter Assay {#sec4.8}
-------------------------

Immortalized SVCs stably expressing 7TFP were grown to confluence in type I collagen-coated 24-well plates in complete growth media, then treated with indicated concentrations of iCRT14 (or DMSO) in serum-free media for 24 hr. Cell lysates were harvested in passive lysis buffer, and reporter activity was measured using the Luciferase Assay System (Promega) and a Veritas Microplate Luminometer (Turner Biosystems). Data were normalized to protein concentration.

Statistical Analysis {#sec4.9}
--------------------

Statistical analyses for association studies between *LRP5* SNPs and quantitative traits were performed using the PLINK program v.1.07 ([http://pngu.mgh.harvard.edu/∼purcell/plink/](http://pngu.mgh.harvard.edu/%7Epurcell/plink/){#intref0025}) ([@bib36]). All quantitative traits were log transformed and analyzed with a linear regression model. Data were adjusted for age, gender, and BMI. Significance is presented as empirical p values as calculated by the additional implementation of permutation procedures (default under PLINK) to the linear regression model. For parametric data, statistical significance was determined by pairwise comparisons using a two-tailed paired or unpaired Student's t test, as appropriate. For non-parametric data, group differences were determined using the Kruskal-Wallis one-way analysis of variance. Statistical significance was determined by pairwise comparisons using a two-tailed Mann-Whitney test. Statistical tests generating a p \< 0.05 were considered significant. Partial correlations of non-parametric data were performed using the SPSS Statistics software package and adjusted for age, gender, and BMI. For studies of the HBM cohort, matched analyses used radius matching based on age, gender, and BMI with a 3:1 ratio, using a multi-level regression model clustering by match set. All data are presented as means ± SEM unless otherwise stated.
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![*LRP5* Expression in Human SC Abdominal, Gluteal, and Visceral WAT\
(A and B) *LRP5* mRNA levels in (A) paired SC abdominal (Abdo) and gluteal (Glut) fat biopsies from lean and obese subjects (n = 20/group) and (B) paired SC abdominal and visceral fat biopsies from 16 individuals undergoing surgery. n = 7 women (age 43.6 ± 15.1 years \[range 21.2--61\]; BMI 30.0 ± 9.1 kg/m^2^ \[range 19.1--42\]) and 9 men (age 63.9 ± 9.3 years \[range 48--76\]; BMI 26.5 ± 5 kg/m^2^ \[range 18.9--33.7\]). Age and BMI are means ± SD.\
(C) *RSPO3* mRNA levels in paired visceral versus SC abdominal fat (n = 16) and SC abdominal versus gluteal fat (n = 20).\
(D) *LRP5* mRNA levels in cultured SVCs (n = 25) and mature adipocytes (ADS) (n = 24).\
(E) Western blot and protein densitometry of LRP5 in immortalized (im) and primary (n = 5 pairs) SVCs from healthy subjects. A, abdominal; G, gluteal.\
(F) *LRP5* mRNA levels in differentiating primary abdominal and gluteal SVCs (n = 5 pairs).\
(G) Comparisons of *LRP5* mRNA levels in paired SC abdominal and gluteal WAT from women with gynoid (WC \< 80 cm, n = 23) versus android (WC ≥ 80 cm, n = 24) fat distribution.\
qRT-PCR data were normalized to *PGK1* and *PPIA* (A--C and G) and to *18S* (D and F). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, corrected for multiple testing. Histogram data are means ± SEM. See also [Tables S6](#app2){ref-type="sec"}, [S7](#app2){ref-type="sec"}, and [S8](#app2){ref-type="sec"}.](gr1){#fig1}

![*LRP5* KD in Immortalized Abdominal and Gluteal SVCs Alters Cell Proliferation and Adipogenesis\
(A) *LRP5* KD was confirmed by qRT-PCR and western blot analyses. *LRP6* mRNA expression was not altered by *LRP5* KD. shCON, control; sh400, *LRP5*-KD cells. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. α-tubulin was used as a western blot loading control.\
(B) Doubling time of shCON and sh400 abdominal and gluteal SVCs. ^∗^p \< 0.05, ^∗∗^p \< 0.01, shCON versus sh400; ^\#^p \< 0.05, Abdo-sh400 versus Glut-sh400.\
(C) Representative micrographs of shCON and sh400 abdominal and gluteal SVCs at day 14 of adipogenic differentiation and histogram showing relative lipid accumulation, assessed by AdipoRed staining (n = 42 wells/group). ^∗∗∗^p \< 0.001.\
(D and E) Relative mRNA levels of adipogenic genes *CEBPA*, *FABP4*, and *PPARG2* in (D) abdominal and (E) gluteal cells at baseline (d0) and day 14 (d14) of adipogenic differentiation. shCON versus sh400 cells: ^\#^p \< 0.01; d0 versus d14 cells: ^a^p \< 0.05, ^b^p \< 0.01. Histogram data are means ± SEM. qRT-PCR data were normalized to *18S*. n = 5--7 independent experiments. See also [Figures S1](#app2){ref-type="sec"}, [S3](#app2){ref-type="sec"}, and [S4](#app2){ref-type="sec"}.](gr2){#fig2}

![Effect of *LRP5* KD on Canonical and Non-Canonical WNT and Insulin Signaling Pathways in Abdominal and Gluteal SVCs\
(A) Western blots for pLRP5/6-Ser1490, active β-catenin, pJNK, and pCAMK2A and qRT-PCR analyses of *AXIN2* and *IL6*, in control (shCON) and *LRP5*-KD (sh400) abdominal and gluteal immortalized SVCs. α-tubulin, total-JNK (tJNK), and total CAMK2A (tCAMK2A) were western blot loading controls. ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
(B) Representative western blots of shCON and sh400 abdominal and gluteal immortalized SVCs stimulated with 100 nM insulin for indicated duration. ^∗^non-specific band, used as loading control.\
(C) *INSR* mRNA levels in shCON and sh400 abdominal and gluteal immortalized SVCs.\
(D) Representative western blots of shCON and sh400 abdominal and gluteal primary (1°) SVCs stimulated with 10 nM insulin for indicated duration. ^∗^non-specific band detected with anti-pIRS1 (Y612) rabbit pAb, ^∗∗^non-specific band detected with anti-LRP5 rabbit mAb, used as loading controls. Histogram data are means ± SEM. n = 5--7 independent experiments. qRT-PCR data were normalized to *18S*. See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![*LRP5*-KD in Abdominal and Gluteal SVCs Dose-Dependently Modulates β-Catenin Signaling\
(A) Protein densitometry of LRP5, pLRP5/6-S1490, and active β-catenin in Abdo-sh401, Abdo-sh400, Glut-sh401, and Glut-sh400 SVCs. Densitometry data were normalized to α-tubulin and are shown relative to their respective shCON levels. n = 3--4 independent experiments.\
(B) Gene expression profiling of β-catenin target genes in Abdo-sh401, Abdo-sh400, Glut-sh401, and Glut-sh400 SVCs. mRNA data were normalized to *18S* and are shown relative to their respective shCON levels. n = 4--7 independent experiments.\
(C) Treatment with the β-catenin small-molecule inhibitor iCRT14 dose-dependently modulates TOPflash promoter activity, adipogenesis, and proliferation in immortalized abdominal and gluteal SVCs (n = 6--7 replicates). Histogram data are means ± SEM. ^∗,\#^p \< 0.05, ^∗∗,\#\#^p \< 0.01, ^∗∗∗^p \< 0.001. ^∗,∗∗,∗∗∗^ within group comparisons; ^\#,\#\#^ between group comparisons.](gr4){#fig4}

###### 

Anthropometry, Plasma Biochemistry, and DXA-Derived Measures of Body Fat Distribution of HBM Patients with *LRP5* Gain-of-Function Mutations from Three Kindreds versus Those of Their Age-, Gender-, and BMI-Matched OBB Controls

                                            S1                                      Controls for S1                                     S2                                      Controls for S2                                    S3                                                                         Controls for S3                                     S4                                      Controls for S4                                    S5                                      Controls for S5                                    S6                                      Controls for S6
  ----------------------------------------- --------------------------------------- --------------------------------------------------- --------------------------------------- -------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------- -------------------------------------------------- --------------------------------------- -------------------------------------------------- --------------------------------------- ---------------------------------------------------
  **n**                                     **--**                                  **129 (77**[a](#tblfn1){ref-type="table-fn"}**)**   **--**                                  **74 (42**[a](#tblfn1){ref-type="table-fn"}**)**   **--**                                                                     **105 (65**[a](#tblfn1){ref-type="table-fn"}**)**   **--**                                  **51 (33**[a](#tblfn1){ref-type="table-fn"}**)**   **--**                                  **55 (33**[a](#tblfn1){ref-type="table-fn"}**)**   **--**                                  **102 (59**[a](#tblfn1){ref-type="table-fn"}**)**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Age (years)                               45                                      44.8 (44.3--45.2)                                   68[c](#tblfn3){ref-type="table-fn"}     49.1 (48.9--49.3)                                  50[c](#tblfn3){ref-type="table-fn"}                                        48.0 (47.7--48.4)                                   28[c](#tblfn3){ref-type="table-fn"}     31.9 (31.5--32.2)                                  38                                      38.1 (36.9--39.3)                                  34[c](#tblfn3){ref-type="table-fn"}     34.6 (34.1--35.1)
  Gender                                    F                                       F                                                   F                                       F                                                  F                                                                          F                                                   M                                       M                                                  F                                       F                                                  M                                       M
  BMI (kg/m^2^)                             27.2                                    27.2 (27.1--27.3)                                   27.3                                    27.2 (27.0--27.3)                                  26.0                                                                       26.0 (25.9--26.0)                                   21.8                                    22.0 (21.8--22.1)                                  35.1                                    35.0 (34.8--35.2)                                  28.8[c](#tblfn3){ref-type="table-fn"}   28.4 (28.2--28.5)
  HOMA-IR                                   0.6[c](#tblfn3){ref-type="table-fn"}    1.7 (1.6--1.8)                                      1.7                                     1.7 (1.6--1.9)                                     1.6[b](#tblfn2){ref-type="table-fn"}^,^[c](#tblfn3){ref-type="table-fn"}   1.7 (1.6--1.8)                                      0.6[c](#tblfn3){ref-type="table-fn"}    1.5 (1.3--1.6)                                     1.2[c](#tblfn3){ref-type="table-fn"}    2.4 (2.1--2.7)                                     1.3[c](#tblfn3){ref-type="table-fn"}    2.1 (2.0--2.3)
  Tissue legs, % fat                        43.5[c](#tblfn3){ref-type="table-fn"}   40.0 (38.9--41.1)                                   44.2[c](#tblfn3){ref-type="table-fn"}   39.6 (38.1--41.0)                                  48.4[c](#tblfn3){ref-type="table-fn"}                                      39.8 (38.7--40.8)                                   19.7                                    20.5 (18.9--22.1)                                  50.2[c](#tblfn3){ref-type="table-fn"}   45.0 (43.1--46.8)                                  31.1[c](#tblfn3){ref-type="table-fn"}   26.4 (25.1--27.6)
  Tissue android, % fat                     35.6[c](#tblfn3){ref-type="table-fn"}   41.5 (40.0--42.9)                                   43.7                                    42.4 (40.2--44.7)                                  43.9[c](#tblfn3){ref-type="table-fn"}                                      41.1 (39.4--42.8)                                   11.6[c](#tblfn3){ref-type="table-fn"}   21.0 (18.5--23.5)                                  55.3                                    53.9 (52.3--55.5)                                  35.5[c](#tblfn3){ref-type="table-fn"}   39.6 (38.3--40.9)
  Android:leg fat ratio (%)                 16.4[c](#tblfn3){ref-type="table-fn"}   22.6 (21.1--24.1)                                   21.5[c](#tblfn3){ref-type="table-fn"}   24.7 (22.0--27.3)                                  18.9[c](#tblfn3){ref-type="table-fn"}                                      23.2 (21.4--25.0)                                   11.0[c](#tblfn3){ref-type="table-fn"}   22.0 (19.7--24.4)                                  21.5[c](#tblfn3){ref-type="table-fn"}   29.2 (26.3--32.1)                                  24.8[c](#tblfn3){ref-type="table-fn"}   35.9 (33.8--37.9)
  Android:total fat ratio (%)               6.7[c](#tblfn3){ref-type="table-fn"}    7.8 (7.6--8.1)                                      7.5[c](#tblfn3){ref-type="table-fn"}    8.2 (7.7--8.6)                                     7.0[c](#tblfn3){ref-type="table-fn"}                                       7.9 (7.6--8.2)                                      4.3[c](#tblfn3){ref-type="table-fn"}    7.1 (6.6--7.5)                                     8.6[c](#tblfn3){ref-type="table-fn"}    9.3 (8.9--9.8)                                     8.6[c](#tblfn3){ref-type="table-fn"}    9.8 (9.6--10.1)
  Central:peripheral fat mass ratio (g/g)   12.9[c](#tblfn3){ref-type="table-fn"}   17.0 (16.0--18.0)                                   16.3[c](#tblfn3){ref-type="table-fn"}   18.4 (16.6--20.1)                                  14.1[c](#tblfn3){ref-type="table-fn"}                                      17.4 (16.2--18.6)                                   8.7[c](#tblfn3){ref-type="table-fn"}    16.9 (15.2--18.6)                                  18.6[c](#tblfn3){ref-type="table-fn"}   21.7 (19.8--23.6)                                  19.1[c](#tblfn3){ref-type="table-fn"}   26.3 (25.0--27.6)

Data for controls are means (95% CI). n, number of age-, gender-, and BMI-matched controls. Subjects from Kindred 1 (S1, S2) and Kindred 2 (S3, S4) carry the A242T mutation; those from Kindred 3 (S5, S6) carry the N198S mutation. NB: We were unable to match subjects S2 and S4 for age. HBM, high bone mass; CI, confidence interval; BMI, body mass index; HOMA-IR, homeostasis model assessment-estimated insulin resistance. See also [Table S2](#app2){ref-type="sec"} and [Figure S1](#app2){ref-type="sec"}.

Number of controls with DXA measurements.

Actual value is below the 95% CI.

Values below/above the 95% CI.

###### 

Comparison of Anthropometry and DXA-Derived Measures of Body Fat Distribution of HBM Subjects With and Without *LRP5* Gain-of-Function Mutations, Matched for Age, Gender, and BMI

                                            *LRP5* HBM (n = 6)   Non-*LRP5* HBM (n = 18)
  ----------------------------------------- -------------------- ----------------------------------------------------
                                            **Mean ± SD**        **Mean (95% CI)**
                                                                 
  Age (years)                               43.0 ± 14.5          41.9 (31.0, 52.7)
  BMI (kg/m^2^)                             27.7 ± 4.3           27.7 (25.5, 29.9)
  Tissue legs, % fat                        39.5 ± 11.8          36.3 (30.3, 42.2)
  Tissue android, % fat                     37.6 ± 14.7          46.8 (40.3, 53.3)[a](#tblfn4){ref-type="table-fn"}
  Android:leg fat ratio (%)                 19.0 ± 4.8           29.5 (26.5, 32.4)[b](#tblfn5){ref-type="table-fn"}
  Android:total fat ratio (%)               7.1 ± 1.6            9.1 (8.4, 9.7)[b](#tblfn5){ref-type="table-fn"}
  Central:peripheral fat mass ratio (g/g)   15.0 ± 3.9           22.0 (19.9, 24.1)[b](#tblfn5){ref-type="table-fn"}

*LRP5* HBM subjects ([Tables 1](#tbl1){ref-type="table"} and [S2](#app2){ref-type="sec"}) were matched with non-*LRP5* HBM subjects on age (within 6 years), sex, and BMI (kg/m^2^), based on radius matching with a ratio 3:1, using a multi-level regression model clustering by match set. HBM, high bone mass; BMI, body mass index; CI, confidence interval. See also [Table S1](#app2){ref-type="sec"}.

p \< 0.05.

p ≤ 0.001.

###### 

Association Studies of the BMD-Associated *LRP5* SNP Rs599083 and DXA-Derived Measures of Body Fat Distribution of Subjects from the Oxford Biobank

                                   Rs599083                                                                                                       
  -------------------------------- --------------------------------------------- -------- ------- --------------------------------------- ------- -------
  **Trait**                        **p value**                                   **β**    **n**   **p value**                             **β**   **n**
                                                                                                                                                  
  Tissue leg, % fat                0.4                                           0.007    3,289   1                                       0.002   3,289
  Tissue android, % fat            0.004[a](#tblfn6){ref-type="table-fn"}        0.033    3,289   0.02[a](#tblfn6){ref-type="table-fn"}   0.027   3,289
  Android:leg fat ratio (%)        0.008[a](#tblfn6){ref-type="table-fn"}        0.028    3,289   0.02[a](#tblfn6){ref-type="table-fn"}   0.025   3,289
  Android:total fat ratio (%)      0.006[a](#tblfn6){ref-type="table-fn"}        0.031    3,289   0.01[a](#tblfn6){ref-type="table-fn"}   0.027   3,289
  Central:peripheral ratio (g/g)   0.007 [a](#tblfn6){ref-type="table-fn"}       0.028    3,289   0.02[a](#tblfn6){ref-type="table-fn"}   0.024   3,289
  BMD (g/cm^2^)                    9 × 10^−5^[a](#tblfn6){ref-type="table-fn"}   −0.058   3,289   --                                      --      --

Effect allele: guanine nucleotide. Effect allele frequency: 0.34. BMD, bone mineral density; p value, empirical p value; β, standardized beta value; n, number of subjects. Data are from 1,438 men and 1,851 women. See also [Tables S3--S5](#app2){ref-type="sec"} and [Figure S2](#app2){ref-type="sec"}.

Significant p values.
